IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
Status:
Completed
Trial end date:
2020-03-22
Target enrollment:
Participant gender:
Summary
This is a multicentric randomized phase III trial comparing intensity-modulated radiotherapy
(75 Gy) plus cisplatin versus conventional radiotherapy (70 Gy) plus cisplatin in patients
with stage III-IV squamous cell carcinoma of oral cavity, oropharynx or hypopharynx. The main
end points are the rate of locoregional control and the rate of xerostomia at 2 years.